BBOT begins trading on Nasdaq after $382M SPAC merger completion Aug 11, 2025 04:30PM
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition Aug 11, 2025 04:30PM